Genotoxicity, Genotype and Marketing - Clinical Research Informer

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

Genotoxicity

Genotype

Marketing

Treatment of Metastatic Triple-Negative Breast Cancer

The Pharma Data

MARCH 25, 2021

The validation of our EU marketing application is an important step toward addressing the significant unmet medical need for people with metastatic triple-negative breast cancer.”. including final safety information for prescribers) will be assessed as part of ongoing and future Marketing Authorization Applications.

Genotoxicity

Genotoxicity Genotype Containment Protein

Trodelvy®, the First Treatment for Metastatic Triple-Negative Breast Cancer Shown to Improve Progression-Free Survival and Overall Survival

The Pharma Data

APRIL 7, 2021

The European Medicines Agency has also validated a Marketing Authorization Application for Trodelvy in the European Union. The incidence of Grade 3-4 neutropenia in genotyped patients was 69% in patients homozygous for the UGT1A1*28, 48% in patients heterozygous for the UGT1A1*28 allele and 46% in patients homozygous for the wild-type allele.

HR Genotype FDA Approval Genotoxicity

Treatment of Metastatic Triple-Negative Breast Cancer

Trodelvy®, the First Treatment for Metastatic Triple-Negative Breast Cancer Shown to Improve Progression-Free Survival and Overall Survival

Stay Connected